The next CRCL/CLB seminar will take place Friday the 3rd of March, at 11.30am in the ONCORA meeting room (Centre Léon Bérard, 2nd floor). We are pleased to welcome Silvia Giordana (Turino). More information will come soon.
Save the date : 4th ANRS HBV Cure Workshop
May 16th 2017 - Espace Saint-Martin - 75003 Paris -
Preliminary program click here
The 3rd CRCL Symposium will welcome you on the 25th-27th September 2017 ! More information on our website here.
MANY THANKS !
The 1st International Symposium "Immune Responses in Cancer and Infection" jointly organized by the CRCL and the CIRI (International Research Centre in Infectiology) took place recently in Lyon. It was a great pleaser to welcome 20 international speakers as well as a total of 380 participants! We thank our sponsors and partners which help us to organize this event! Many thanks again.
We can still access to the final program: click here
Follow the CRCL news on Twitter!
Communiqué de presse : SANOFI-INSERM HBV Cure program: a medical, academic and pharmaceutical alliance for research on Hepatitis B. Cliquez ici
Création d'un Laboratoire International Associé (LIA) entre l'équipe CRCL d'Alain Puisieux "EMT et plasticité des cellules cancéreuses" et l'équipe de Frédéric Hollande "Molecular Mechanisms of Tumour Progression" du Victorian Comprehensive Cancer Centre (Université de Melbourne, Australie).
There are several positions available at the CRCL: click here
A postdoc position in onco-immunology is available in C. Caux's lab : click here
Postdoc in tumor immunology: click here
A postdoc position in the team of F. Zoulim : click here
Other positions 2016
- A Computational Biologist/Immunology position is available in the team of C. Caux and JY Blay. click here
- Other postdoc positions are available in the teams of M. Gabut and J. Marie: click here
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
29 November 2016
This work involved the team of Alain Puisieux.
Targeted therapies with MAPK inhibitors (MAPKi) are faced with severe problems of resistance in BRAF-mutant melanoma. In parallel to the acquisition of genetic mutations, melanoma cells may also adapt to the drugs through phenotype switching. The ZEB1 transcription factor, a known inducer of EMT and invasiveness, is now considered as a genuine oncogenic factor required for tumor initiation, cancer cell plasticity, and drug resistance in carcinomas. Here, we show that high levels of ZEB1 expression are associated with inherent resistance to MAPKi in BRAFV600-mutated cell lines and tumors.
PubMed access: click here
Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers
25 March 2016
This study involves the team of Patrick Mehlen.
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
PubMed access: click here